Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients.

Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients.
Br J Dermatol. 2020 Sep 30;:
Authors: Nettis E, Fabbrocini G, Ortoncelli M, Pellacani G, Argenziano G, Di Leo E, Patruno C, Stingeni L, Foti C, Rongioletti F, Macchia L, Tavecchio S, Napolitano M, Ribero S, Bonzano L, Calabrese G, Di Bona D, Nisticò SP, Hansel K, Romita P, Piras V, Carbonara M, Detoraki A, Ferrucci SM
Abstract
Dupilumab, an inhibitor of interleukin (IL)-4/13 activity, is a biological agent approved for the treatment of moderate-to-severe atopic dermatitis (AD)1 . Our aim was to assess the long-term effectiveness and safety of dupilumab in a clinical real-life setting.
PMID: 32998177 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - September 29, 2020 Category: Dermatology Authors: Nettis E, Fabbrocini G, Ortoncelli M, Pellacani G, Argenziano G, Di Leo E, Patruno C, Stingeni L, Foti C, Rongioletti F, Macchia L, Tavecchio S, Napolitano M, Ribero S, Bonzano L, Calabrese G, Di Bona D, Nisticò SP, Hansel K, Romita P, Piras V, Carbonara Tags: Br J Dermatol Source Type: research